Anti-Thrombogenic Additive Technology for Surface Modification of Medical Devices
Low molecular weight additives providing passive surface modification
Endexo® surface modifying macromolecules enhance the biocompatibility of medical devices that come in contact with blood, tissue, or other biological fluids. They are low molecular weight fluoro-oligomeric additives that migrate to the top few nanometers of the device surface during the manufacturing process.
In the presence of blood, the modified surfaces are able to suppress procoagulant protein conformation, reduce platelet adhesion and inhibit platelet activation. In the presence of bacteria mediated fluids the modified surfaces are effective at reducing bacteria adhesion (up to 5 log CFU) and encrustation. Endexo® modified devices reduce thrombosis, infection and biofouling all without the use of drugs.
Endexo® platform technology can be applied to a variety of base polymers (e.g. polyurethane, polysulfone, PVC, polypropylene, and silicone) and manufacturing techniques (e.g. extrusion, solution spinning, and injection molding). Endexo® molecules become an integral part of the base material providing durable surface modification and extended efficacy compared to traditional coatings.
Advantages of Endexo® anti-thrombogenic additive technology
Passive surface modification
Permanent presence on all device surfaces
No impact on device functionality
No change to existing manufacturing processes
Compatible with a wide range of base polymers
Low cost technology
Commercial application of Endexo® anti-thrombogenic additive technology
Average reduction across 8,500 BioFlo™ PICCs studied (as reported by AngioDynamics):
Reduction of 50% deep vein thrombosis
Reduction of 59% tissue plasminogen activator
Source: ANGO FDA Approval documents; Needham & Company 14th Annual Healthcare Conference, April 14, 2015